Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment
Abstract Atezolizumab, a biotherapeutic monoclonal antibody directed against PD-L1, has been shown to be efficacious in multiple oncology indications. In clinical trials, a subset of patients developed anti-atezolizumab antibodies, necessitating the development of a neutralizing antibody (NAb) assay...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SpringerOpen
2025-02-01
|
| Cyfres: | AAPS Open |
| Mynediad Ar-lein: | https://doi.org/10.1186/s41120-024-00105-z |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|